Abstract 388P
Background
More and more evidences suggest that circulating tumor cells (CTC) may be a good biomarker, not only as a prognostic indicator for tumors, but also for monitoring therapeutic effect and recurrence. However, the detection of CTC usually requires the final artificial judgment. This requires experienced pathologists and increases their workload. The application of machine learning in medical image recognition can effectively improve the level of automation and reduce the workload. So we hope to use machine learning to identify CTCs.
Methods
First, the python's openCV software package is used to segment the images of CTCs by image denoising, image filtering, edge detection, image expansion and contraction techniques. Secondly, the segmented cell images as a training set are trained using the CNN deep learning network. The CNN deep learning network includes input layer, intermediate hidden layer, and output layer. The middle hidden layer contains three layers, namely layer1, layer2 and lager3. Each intermediate hidden layer further includes convolution layer, excitation layer, and pooling layer. After the input layer, the cell images first enter the first intermediate hidden layer. The convolution layer of the first intermediate hidden layer is composed of 32 5x5 convolution kernels, which are then output to the pooling layer for dimension reduction through the ReLU excitation layer. After dimension reduction, the data is output from the first hidden layer to complete an entire feature extraction process. Then, through the second and third intermediate hidden layers in sequence, all feature extraction is completed. Finally, it enters the output layer and output the result, ie, CTCs or non-CTCs.
Results
We took 2920 cells from 732 patients for training and testing. Among them, 2000 cells were used as training set and 920 cells were used as testing set. The sensitivity and specificity of recognition reached 86.1% and 84.5%, respectively.
Conclusions
To identify CTC by machine learning can reach high sensitivity and specificity. We are further revising our methods of deep learning to achieve greater recognition effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract